Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this survey is to evaluate the long-term safety and efficacy of leuprorelin acetate injection kit 11.25 mg in patients with spinal and bulbar muscular atrophy (SBMA) in the routine clinical setting.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• All SBMA patients who have been confirmed as receiving the drug
Locations
Other Locations
Japan
Takeda Selected Site
RECRUITING
Tokyo
Contact Information
Primary
Takeda Study Registration Call Center
medicalinformation@tpna.com
+1-877-825-3327
Time Frame
Start Date: 2017-11-02
Estimated Completion Date: 2026-04-30
Participants
Target number of participants: 1890
Treatments
Leuprorelin Acetate 11.25 mg
Leuprorelin Acetate Injection Kit 11.25 mg, every 12 weeks subcutaneously, for up to at most 8 years. Participants received interventions as part of routine medical care.
Related Therapeutic Areas
Sponsors
Leads: Takeda